Pulse Biosciences Merges with Lumena Pharmaceuticals

TL;DR

Pulse Biosciences is now Lumena Pharmaceuticals, trading as LUMNA on Nasdaq after stockholder approval.

AI Summary

On July 8, 2024, Pulse Biosciences, Inc. filed an 8-K report detailing the closing of its previously announced business combination with privately held company, privately held company, Lumena Pharmaceuticals, Inc. The transaction was approved by Pulse Biosciences' stockholders on July 5, 2024. Following the closing, the combined company will operate under the name Lumena Pharmaceuticals, Inc. and will trade under the ticker symbol 'LUMNA' on the Nasdaq Capital Market.

Why It Matters

This merger signifies a strategic shift for Pulse Biosciences, potentially unlocking new growth avenues and market opportunities under the Lumena Pharmaceuticals banner.

Risk Assessment

Risk Level: medium — Mergers and acquisitions carry inherent risks related to integration, market reception, and achieving projected synergies.

Key Players & Entities

• Pulse Biosciences, Inc. (company) — Registrant
• Lumena Pharmaceuticals, Inc. (company) — Acquired company and new combined entity name
• July 8, 2024 (date) — Date of 8-K filing and closing of business combination
• July 5, 2024 (date) — Date of stockholder approval for the business combination
• Nasdaq Capital Market (company) — Exchange where the combined company will trade
• LUMNA (ticker) — New ticker symbol for the combined company

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock , par value $0.001 per share PLSE The Nasdaq Stock Mar

Filing Documents

• plse20240708_8k.htm (8-K) — 29KB
• ex_695850.htm (EX-99.1) — 15KB
• 0001437749-24-022297.txt ( ) — 178KB
• plse-20240708.xsd (EX-101.SCH) — 3KB
• plse-20240708_def.xml (EX-101.DEF) — 11KB
• plse-20240708_lab.xml (EX-101.LAB) — 15KB
• plse-20240708_pre.xml (EX-101.PRE) — 11KB
• plse20240708_8k_htm.xml (XML) — 3KB

01

ITEM 8.01 Other Events. On July 8, 2024, Pulse Biosciences, Inc. (the "Company") issued a press release announcing that it has received Breakthrough Device Designation from the U.S. Food and Drug Administration ("FDA") for the Company's CellFX nsPFA Cardiac Surgery System for the treatment of atrial fibrillation. The FDA's Breakthrough Devices Program is a voluntary program for certain medical devices that potentially provide for more effective treatment or diagnosis of a life-threatening or irreversibly debilitating disease or condition. The program is designed to expedite the development and review of these medical devices. The Company's Cardiac Surgery System with Surgical Clamp is designed to produce durable, continuous, transmural ablation lesions during cardiac surgery procedures for the treatment of atrial fibrillation. The bipolar clamp utilizes the Company's proprietary nanosecond PFA technology. A copy of the press release related to the matters set forth herein is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release issued by Pulse Biosciences, Inc. dated July 8, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PULSE BIOSCIENCES, INC. Date: July 8, 2024 By: /s/ Burke T. Barrett Burke T. Barrett President and Chief Executive Officer (Principal Executive and Principal Financial Officer)

View Full Filing

View this 8-K filing on SEC EDGAR